Journal Article

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Li, Weiming, Chen, Zi, Liang, Yang, Song, Yongping, Meng, Li, Wang, Hengbang, Qin, Yazhen, Zhu, Huanling, Men, Lichuang, Xu, Na, Huang, Xiaojun, Liu, Xiaoli, Zhang, Yanli, Chen, Suning, Du, Xin, Zhai, Yifan, Liu, Bingcheng, Li, Zongru, Lu, Ming, Jiang, Qian, Yang, Dajun, Hu, Yu, Niu, Qian

2022

Overview

Background BCR-ABL1 T315I mutations confer resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Olverembatinib is a new potent BCR-ABL1 TKI with preclinical activity against T315I-mutated CML. In phase 1/2 studies, we explored the safety and efficacy of olverembatinib in Chinese adults with TKI-resistant CML in the chronic phase (CML-CP) and accelerated phase (CML-AP). Methods In the phase 1 study, olverembatinib was orally administered once every other day in 28-day cycles at 11 dose cohorts ranging from 1 to 60 mg, and we evaluated the maximum tolerated dose, recommended phase 2 dose (RP2D), safety, efficacy, and pharmacokinetics of olverembatinib. In the phase 2 studies, olverembatinib was administered at the RP2D of 40 mg orally on alternate days for 28-day cycles. The primary outcome measure is major cytogenetic response (MCyR) and major hematologic response by the end of Cycle 12 in CML-CP and CML-AP, respectively. Fine and Gray's hazard models were used to identify covariates associated with responses. Results A total of 165 patients (> 80.0% of whom had received ≥ 2 TKIs) were enrolled in this study. Among 127 patients with CML-CP, the 3-year cumulative incidences of achieving MCyR, complete cytogenetic response (CCyR), major molecular response (MMR), MR 4.0 , and MR 4.5 were 79.0, 69.0, 56.0, 44.0 and 39.0%, respectively. The highest response rates were observed in patients with a single T315I mutation. Among 38 patients with CML-AP, the 3-year cumulative incidences of achieving MCyR, CCyR, MMR, MR 4.0 , and MR 4.5 were 47.4%, 47.4%, 44.7%, 39.3%, and 32.1%, respectively. In multivariate analyses, baseline BCR-ABL1 mutation status was significantly associated with cytogenetic and molecular responses. Common treatment-related adverse events included skin hyperpigmentation, hypertriglyceridemia, proteinuria, and severe thrombocytopenia. Conclusions Olverembatinib was well tolerated, with significant antileukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation. Trial registration : The phase 1 trial is registered at CTR20220566, and the two single-arm, open-label phase 2 studies are registered at ClinicalTrials.gov: NCT03883087 (CML-CP) and NCT03883100 (CML-AP).

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Accelerated phase / Adult / Analysis / Angiogenesis Inhibitors - therapeutic use / Bone marrow / Cancer Research / Care and treatment / Cell cycle / Censorship / Chronic myeloid leukemia / Chronic phase / Cytogenetics / Drug Resistance, Neoplasm / Enzyme inhibitors / Fusion Proteins, bcr-abl - genetics / Hematology / Humans / Hyperpigmentation / Hypertriglyceridemia / Kinases / Laboratories / Leukemia / Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy / Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics / Medicine / Medicine & Public Health / Mutation / Myeloid leukemia / Oncology / Oral administration / Patients / Pharmacokinetics / Phenols / Product development / Protein Kinase Inhibitors - pharmacology / Protein Kinase Inhibitors - therapeutic use / Proteinuria / T315I mutation / Thrombocytopenia / Tyrosine / Tyrosine kinase inhibitor / Tyrosine kinase inhibitors